Business Context and Reporting Period
Company: Evotec SE (Evotec AG)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Six months ended June 30, 2008
Key Event: On May 2, 2008, Evotec completed the acquisition of Renovis, Inc. via a share-for-share transaction, issuing approximately 35 million new shares. This acquisition marks a strategic transformation into a biopharmaceutical company with a focus on Central Nervous System (CNS) drug discovery.
Key Financial Metrics
| Metric | H1 2008 | H1 2007 (Restated) |
|---|---|---|
| Revenue | EUR 14.5 million | EUR 15.8 million |
| Gross Margin | 25.2% | 20.2% |
| Operating Loss | EUR 26.9 million | EUR 23.6 million |
| Net Loss | EUR 25.9 million | EUR 22.1 million |
| R&D Expenses | EUR 21.9 million | EUR 16.4 million |
| Liquidity (Cash + Investments) | EUR 101.0 million | EUR 93.7 million (Dec 31, 2007) |
| Loss Per Share (Basic/Diluted) | EUR (0.31) | EUR (0.32) |
Note: H1 2008 results include Renovis operations from May 2, 2008. H1 2007 results are restated to exclude discontinued operations (Chemical Development Business sold in late 2007).
Material Changes vs. Prior Period
- Revenue Decline: Reported revenue decreased 8% year-over-year primarily due to the weakening of the US dollar against the Euro. At constant 2007 currency rates, revenue would have been EUR 16.1 million (a slight increase).
- Increased Operating Loss: The operating loss widened to EUR 26.9 million, driven by a 33% increase in R&D expenses. This increase is attributed to a milestone payment to Roche for the EVT 302 Phase II trial and the inclusion of Renovis R&D costs.
- Liquidity Position: Total liquidity increased to EUR 101.0 million. However, the company recorded an unrealized translation loss of approximately EUR 4.6 million on liquid assets held in USD and GBP. Adjusted for year-end 2007 exchange rates, liquidity would have been EUR 105.6 million.
- Capital Structure: Share count increased significantly due to the issuance of 34,970,268 new ordinary shares to Renovis shareholders.
Guidance, Outlook, and Risks
2008 Financial Guidance
- Revenue: Expected to be between EUR 34 million and EUR 36 million (excluding potential out-licensing income).
- Operating Result: Expected to be in the same range as 2007 absent impairment charges or out-licensing income. Successful out-licensing could significantly improve results.
- R&D Expenses: Expected to be at the lower end of the EUR 46 million to EUR 51 million range (excluding share-based compensation).
- Liquidity: Year-end 2008 liquidity is projected to exceed EUR 85 million at constant 2007 currencies (approx. EUR 80 million at current rates). Management believes this is sufficient to fund development programs through the end of 2010 without a major partnering event.
Clinical Pipeline Progress
- EVT 101 (Alzheimer's/Pain): Phase Ib study results showed the drug was well tolerated up to the highest dose tested.
- VR1 Antagonist (Pain/Inflammation): Pfizer initiated a Phase I clinical trial under collaboration.
- EVT 302 (Smoking Cessation): Phase II exploratory study results expected in Q3 2008. A EUR 2.7 million milestone payment to Roche was made in July 2008.
- P2X7 Antagonist: On track to enter Phase I in Q3 2008.
Risks and Contingencies
- Currency Risk: Adverse exchange rate movements between the Euro, USD, and GBP impact reported revenue and liquidity.
- Partnership Risk: The company is actively seeking a partner for its lead insomnia candidate, EVT 201. Failure to secure a partner or delay in milestone payments could impact cash flow.
- Clinical Risk: Inherent risks of clinical development, including potential failure of product candidates or regulatory delays.
- Auction Rate Securities: The company holds EUR 8.3 million in auction rate securities, which have been impaired by approximately 8.4% due to market conditions.
Investor Verification Checklist
- Renovis Integration: Verify the timeline and financial impact of the Renovis acquisition, specifically the inclusion of R&D costs in Q2 2008.
- Currency Impact: Confirm the sensitivity of revenue and liquidity projections to fluctuations in the USD/EUR and GBP/EUR exchange rates.
- Partnership Status: Monitor progress on the EVT 201 (insomnia) partnering discussions, as this is a key value driver.
- Liquidity Runway: Validate the EUR 80 million year-end liquidity target against actual cash burn rates and the EUR 2.7 million Roche milestone payment.
- Auction Rate Securities: Assess the valuation and liquidity risk associated with the EUR 8.3 million holding in auction rate securities.